Search Within

Friedhelm Helling

Formats
  1. Journal Article (11)
  2. Meeting Abstract (4)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (3)
  2. Melanoma Disease Management Team (3)
  3. Melanoma and Immunotherapeutics Service (3)
  4. Solid Tumor Oncology Division (3)
  5. Sloan Kettering Institute Postdocs (1)
People
  1. Philip Livingston (16)
  2. Shengle Zhang (7)
  3. Sucharita Adluri (7)
  4. Herbert Oettgen (5)
  5. Michele Jones Calves (5)
  6. Kenneth Lloyd (4)

More People

Years
  1. 1997 (1)
  2. 1996 (2)
  3. 1995 (4)
  4. 1994 (6)
  5. 1993 (3)
Publications
  1. Proceedings of the American Association for Cancer Research Annual Meeting (4)
  2. Cancer Research (3)
  3. Cancer Immunology, Immunotherapy (2)
  4. Vaccine (2)
  5. Annals of the New York Academy of Sciences (1)
  6. International Journal of Cancer (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. Elsevier Inc. (2)
  3. John Wiley & Sons (2)
  4. Springer (2)
  5. American Society of Clinical Oncology (1)
  6. Humana Press Inc (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies
    Journal Article

    Livingston, P.; Zhang, S.; Adluri, S.; Yao, T. J.; Graeber, L.; Ragupathi, G.; Helling, F.; Fleisher, M.
    Cancer Immunology, Immunotherapy (1997)

    Fulltext@MSK | Save
  • Approaches to augmenting the immunogenicity of synthetic MUC1 peptide in mice
    Meeting Abstract

    Zhang, S.; Graeber, L.; Helling, F.; Ragupathi, G.; Adluri, S.; Lloyd, K. O.; Livingston, P. O.
    Proceedings of the American Association for Cancer Research Annual Meeting (1996)

    Fulltext@MSK | Save
  • Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice
    Journal Article

    Zhang, S.; Graeber, L. A.; Helling, F.; Ragupathi, G.; Adluri, S.; Lloyd, K. O.; Livingston, P. O.
    Cancer Research (1996)

    Fulltext@MSK | Save
  • Effect of active immunization with human tumor associated carbohydrate antigens on the immune response and on tumor growth
    Meeting Abstract

    Livingston, P. O.; Helling, F.; Zhang, S.
    Proceedings of the American Association for Cancer Research Annual Meeting (1995)

    Fulltext@MSK | Save
  • Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine
    Journal Article

    Kitamura, K.; Livingston, P. O.; Fortunato, S. R.; Stockert, E.; Helling, F.; Ritter, G.; Oettgen, H. F.; Old, L. J.
    Proceedings of the National Academy of Sciences of the United States of America (1995)

    Fulltext@MSK | Save
  • G(M2)-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
    Journal Article

    Helling, F.; Zhang, S.; Shang, A.; Adluri, S.; Calves, M.; Koganty, R.; Longenecker, B. M.; Yao, T. J.; Oettgen, H. F.; Livingston, P. O.
    Cancer Research (1995)

    Fulltext@MSK | Save
  • Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides
    Journal Article

    Zhang, S.; Helling, F.; Lloyd, K. O.; Livingston, P. O.
    Cancer Immunology, Immunotherapy (1995)

    Fulltext@MSK | Save
  • Increased complement mediated lysis of neuroectodermal tumor cell lines by combination of monoclonal antibodies
    Meeting Abstract

    Zhang, S. L.; Helling, F.; Livingston, P. O.
    Proceedings of the American Association for Cancer Research Annual Meeting (1994)

    Fulltext@MSK | Save
  • Phase I trial immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma
    Meeting Abstract

    Helling, F.; Livingston, P. O.; Adluri, S.; Shang, A.; Yao, T. J.; Kensil, C. R.; Newman, M. J.; Marciani, D.
    Proceedings of the American Association for Cancer Research Annual Meeting (1994)

    Fulltext@MSK | Save
  • Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
    Journal Article

    Livingston, P. O.; Adluri, S.; Helling, F.; Yao, T. J.; Kensilt, C. R.; Newman, M. J.; Marciani, D.
    Vaccine (1994)

    Fulltext@MSK | Save